Dear Reader,
Welcome to the final issue of the American Journal of Cardiovascular Drugs for 2021.
I wish to reflect on this year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.
In 2021, over 60 articles have been published. The most popular of these in terms of downloads from SpringerLink have been:
Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs 21, 483–486 (2021). https://doi.org/10.1007/s40256-021-00471-z.
Ashton V, Mudarris L, Moore KT. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. Am J Cardiovasc Drugs 21, 283–297 (2021). https://doi.org/10.1007/s40256-020-00434-w.
Galo J, Celli D, Colombo R. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions. Am J Cardiovasc Drugs 21, 267–270 (2021). https://doi.org/10.1007/s40256-020-00445-7.
Vong C, Boucher M, Riley S, et al. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. Am J Cardiovasc Drugs 21, 535–543 (2021). https://doi.org/10.1007/s40256-021-00464-y.
Jensen IS, Wu E, Cyr PL, et al. Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. Am J Cardiovasc Drugs (2021). https://doi.org/10.1007/s40256-021-00491-9.
Veeranki SP, Xiao Z, Levorsen A, et al. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients. Am J Cardiovasc Drugs 21, 443–452 (2021). https://doi.org/10.1007/s40256-020-00456-4.
Social media sharing and other online mentions of information are other metrics with which to measure the reach of articles. This year the following articles published in the American Journal of Cardiovascular Drugs scored highly on the Altmetric system:
Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs 21, 483–486 (2021). https://doi.org/10.1007/s40256-021-00471-z
Jensen IS, Wu E, Cyr PL, et al. Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. Am J Cardiovasc Drugs (2021). https://doi.org/10.1007/s40256-021-00491-9
Ali S, Jung S, Nandkeolyar S, et al. Inpatient Diuretic Management of Acute Heart Failure: A Practical Review. Am J Cardiovasc Drugs (2021). https://doi.org/10.1007/s40256-020-00463-5
Ullah W, Haq S, Zahid S, et al. Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis. Am J Cardiovasc Drugs (2021). https://doi.org/10.1007/s40256-021-00485-7
Wiethorn EE, Bell CM, Wiggins BS. Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing ≥ 120 Kilograms versus 60–120 Kilograms. Am J Cardiovasc Drugs 21, 545–551 (2021). https://doi.org/10.1007/s40256-021-00470-0
The high quality of content published in the American Journal of Cardiovascular Drugs has been reflected in the most recent impact factor of 3.571 (placing the journal in the 2nd quartile of the ‘Cardiac & Cardiovascular Systems’ category) and CiteScore™ of 5.1. (placing the journal in the top quartile of the ‘Cardiology and Cardiovascular Medicine’ category). Further, the American Journal of Cardiovascular Drugs has published content in a timely manner, with an average time from submission to first decision of 27 days.
The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.
I would like to start by thanking the authors of the articles published in the American Journal of Cardiovascular Drugs over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.
The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for the American Journal of Cardiovascular Drugs in the last 12 months:
Antonio Abbate, USA
Hesham Abdelaziz, UK
Alberto Aimo, Italy
Tamas Alexy, USA
Muaamar Al-Gobari, Switzerland
Eisuke Amiya, Japan
Dominick J. Angiolillo, USA
Gabriella Arlotta, Italy
Kamal Awad, Egypt
Assem Aweimer, Germany
Savalan Babapoor-Farrokhran, USA
Khaled Bahjri, USA
Stephen C. Bain, UK
Sudarshan Balla, USA
Alexander E. Berezin, Ukraine
Aikaterini Bilitou, Germany
Paul Billoir, France
Julia L. Boland, USA
Eric Bruckert, France
Revathy Carnagarin, Australia
Ilaria Cavallari, Italy
Tze Fan Chao, Taiwan, Republic of China
Vivek Chaturvedi, India
Yunqing Chen, Republic of China
Gerald Chi, USA
Vijay K. Chopra, India
Rahul Choudhary, India
Arrigo F.G. Cicero, Italy
Alberto Corsini, Italy
Francesco Costa, Italy
Yousef H. Darrat, USA
Anindita Das, USA
Bibhuti B. Das, USA
Bhagwan Dass, USA
Bart De Geest, The Netherlands
Gérard de Pouvourville, France
Saurabh A. Deshpande, India
Simon B. Dimmitt, Australia
Dimitra Dimopoulou, Greece
Ming Ding, USA
Abhinav Diwan, USA
Olivia M. Dong, USA
Peter Donovan, Australia
P. Barton Duell, USA
Andre R. Duraes, Brazil
Hirotoshi Echizen, Japan
Frank Edelmann, Germany
Julia W. Erath, Germany
Michal M. Farkowski, Poland
Nicola Ferri, Italy
Liliana Gadola, Uruguay
Zhu Ye Gao, Republic of China
Brian J. Gates, USA
Gopal C. Ghosh, India
Matthew Griffin, USA
Kendra J. Grubb, USA
Masahide Harada, Japan
Amer Harky, UK
Inmaculada Hernandez, USA
John D. Horowitz, Australia
Philip Houck, USA
Teruhiko Imamura, Japan
W. Yus H. B. W. Isa, Malaysia
Larry R. Jackson II, USA
Boyoung Joung, Republic of Korea
Ankur Kalra, USA
Polydoros N. Kampaktsis, USA
Aditya Kapoor, India
Ganesan Karthikeyan, India
Yu Kataoka, Japan
Ajoe J. Kattoor, USA
Ty H. Kiser, USA
Anastasios Kollias, Greece
Günther Krumpl, Austria
Ashish Kumar, India
Andree Kurniawan, Indonesia
David M. Kwiatkowski, USA
Giovanni Landoni, Italy
Christoph Lange, Germany
Matthew Lee, UK
Gregor Lindner, Switzerland
Suxin Luo, Republic of China
Alessandro Maloberti, Italy
John M. Mandrola, USA
Michel Marre, France
Luis Masana, Spain
Danilo Menichelli, Italy
Marco Metra, Italy
Tanveer Mir, USA
Arshag D. Mooradian, USA
Gary W. Moore, UK
Trefor O. Morgan, Australia
Nuccia Morici, Italy
Zuzana Motovska, Czech Republic
Henning Nilius, Switzerland
Soo Liang Ooi, Australia
Akhil Parashar, USA
Nilang G. Patel, USA
Sabata Pierno, Italy
Alexa Powell, USA
Jun Pu, Republic of China
Mei Qiu, Republic of China
Jeffrey P. Raj, India
Debabrata Roy, UK
Pierre F. Sabouret, France
Omar Saeed, USA
Kalyan Saginala, USA
Yehia Saleh, USA
Luis Sargento, Portugal
Santhosh Satheesh, India
Gianluigi Savarese, Sweden
Stefanie Schüpke, Germany
Martin W. Schwarze, USA
Sebastiano Sciarretta, Italy
Borys O. Shelest, Ukraine
Stephanie J. W. Shoop-Worrall, UK
Ricardo Simões, Brazil
Romain Siriez, Belgium
Alexandre A. S. M. Soares, Brazil
Ilsuk Sohn, Republic of Korea
Xue Song, USA
Stefan Stortecky, Switzerland
George A. Stouffer, USA
Jin-Yu Sun, Republic of China
Juan Tamargo, Spain
Jean-Claude Tardif, Canada
Jorg Taubel, UK
Long To, USA
Anna Toso, Italy
Toshiaki Toyota, Japan
Cynthia M. Tracy, USA
Muhammad S. Usman, Pakistan
Monica Verdoia, Italy
Xin Wang, USA
Gerald F. Watts, Australia
Martin Wawruch, Slovakia
Cezary Wójcik, USA
Zhuomin Wu, Republic of China
Ruijuan Xu, Republic of China
Yugo Yamashita, Japan
Syed A. A. Zaidi, USA
Hong Zhi, Republic of China
Coert J. Zuurbier, The Netherlands
I am also very grateful to the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.
A. Michael Lincoff, Cleveland Clinic Foundation, Cleveland, OH, USA [Consulting Editor]
Ailin Barseghian El-Farra, University of California at Irvine, Irvine, CA, USA
Balram Bhargava, All India Institute of Medical Sciences, New Delhi, India
Deepak L. Bhatt, Brigham and Women’s Hospital Heart & Vascular Center, Boston, MA, USA
Prakash C. Deedwania, University of California at San Francisco, Fresno, CA, USA
Naranjan S. Dhalla, Institute of Cardiovascular Sciences, Winnipeg, MB, Canada
Phillip A. Erwin, South Miami Heart Specialists, South Miami, FL, USA
Arthur M. Feldman, Temple University School of Medicine, Philadelphia, PA, USA
Valentin Fuster, Mount Sinai Medical Center, New York, NY, USA
Xavier Girerd, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Sidney Goldstein, Henry Ford Heart and Vascular Institute, Detroit, MI, USA
Joseph A. Hill, UT Southwestern Medical Center, Dallas, TX, USA
Gowraganahalli Jagadeesh, Silver Spring, MD, USA
Neal S. Kleiman, The Methodist DeBakey Heart Center, Houston, TX, USA
Kornelia Kotseva, Imperial College London, London, UK
Antoine Lafont, Université Paris-Descartes, Paris, France
Thierry H. Le Jemtel, Tulane University Medical School, New Orleans, LA, USA
Mario Marzilli, University of Pisa, Pisa, Italy
Venu Menon, Cleveland Clinic, Cleveland, OH, USA
Gilles Montalescot, Pitié-Salpêtrière University Hospital, Paris, France
Doralisa Morrone, University of Pisa, Pisa, Italy
Stephen G. Nicholls, Monash University, Melbourne, Vic, Australia
Ali Oto, Hacettepe University School of Medicine, Ankara, Turkey
Bertram Pitt, University of Michigan Hospital, Ann Arbor, MI, USA
Silvia G. Priori, Fondazione Salvatore Maugeri, Pavia, Italy
Venkata S. Ram, Texas Blood Pressure Institute, Dallas, TX, USA
Gianpaolo Reboldi, University of Perugia, Perugia, Italy
Gaetano Santulli, Albert Einstein College of Medicine, New York, NY, USA
Johanne Silvain, Institut de Cardiologie, Paris, France
Kewal K. Talwar, Max Super Speciality Hospital, New Delhi, India
Michal Tendera, Medical University of Silesia, Katowice, Poland
Udho Thadani, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Alec Vahanian, Groupe Hospitalier Bichat-Claude Bernard, Paris, France
George W. Vetrovec, Virginia Commonwealth University, Richmond, VA, USA
Michael A. Weber, State University of New York, New York, NY, USA
William S. Weintraub, Christiana Care Health Services, Newark, DE, USA
Harvey D. White, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
Barbara S. Wiggins, Medical University of South Carolina, Charleston, SC, USA
Nathan D. Wong, University of California at Irvine, Irvine, CA, USA
Springer Nature has continued to support the global response to COVID-19 by making all relevant content immediately and freely available. Indeed, the American Journal of Cardiovascular Drugs has published a number of papers relevant to the COVID-19 pandemic that are free to access, including:
Hernandez I, Tadrous M, Magnani JW, et al. Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. Am J Cardiovasc Drugs 21, 581–583 (2021). https://doi.org/10.1007/s40256-021-00475-9.
Kow CS, Hasan SS. The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. Am J Cardiovasc Drugs (2021). https://doi.org/10.1007/s40256-021-00490-w.
Kaesemeyer W, Suvorava T. Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione. Am J Cardiovasc Drugs (2021). https://doi.org/10.1007/s40256-021-00474-w.
In terms of other important company initiatives, the Springer Nature ‘Sustainable Development Goals (SDG) Programme’ is aiming to connect researchers who are tackling the world’s toughest challenges with practitioners in policy and business, while the ‘Women in Science’ initiative aims to help empower more women scientists to achieve scientific excellence. Finally, I am delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet and flights) and earlier this year signed The Climate Pledge, making a commitment to be Net Zero carbon by 2040.
Returning to the American Journal of Cardiovascular Drugs, the editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of cardiovascular therapy over the coming year.
I thank you for your continued support.
With best wishes,
Amitabh Prakash
Editor